Articles

As a worldwide leading expert in the aseptic filling of liquid and lyophilized drugs, Vetter is regularly cited in international media. On this page, you will find recent examples.

• When Choosing a CDMO For Your Organization, Failure Is Never An Option
  Author: Peter Soelkner
  Medium: BioPharm International, October 2011
  For today’s drug companies, especially smaller biotech companies faced with limited financial resources, expertise, people and equipment, it is of critical importance to select the appropriate CDMO outsourcing partner. They can provide vital support by helping to manage processes and facilitate creative decision-making during the early development period. But finding the right CDMO can be a challenging, time-intensive process. Within this article Peter Soelkner, Vetter Managing Director provides guidance with this process by providing answers to commonly asked questions.
• Becoming the Partner of Choice, One Step at a Time
  Author: Peter Soelkner
  Medium: BioPro, October 2011
  Leading companies in the pharmaceutical and biotechnology industry today are demanding, as they should be. Contract development and manufacturing organizations like Vetter are entrused with the jewels of their client i.e., biotechnology and pharmaceutical products worth billions of euros. Of course, producing prefilled drug delivery systems for clients that measure up to exacting and demanding standards of global regulatory authorities requires investment in modern production sites and technology. But success also requires vision and a sound strategy. In an interview with Biotechnology and Life Sciences medium biopro.de, Peter Soelkner, Managing Director of Vetter Pharma International discusses how Vetter has taken a step-by-step approach to achieve a leadership status in this industry over the last 20+ years, and reveals some of the company’s strategies for moving forward in this ever-changing, challenging market.
• What are some of the latest trends and issues facing the global biopharm industry today and how will successful companies manage change?
  Author: Peter Soelkner
  Medium: Pharmaceutical Outsourcing, June 2011
  Numerous and continuous changes in the global market have led to an increasingly competitive and evolving market. Keeping abreast of the latest issues and trends has never been more critical to achieving successful, sustainable growth. Anticipating trends and shifting landscapes, identifying and meeting customer needs, combined with continuous improvements in manufacturing methods to ensure quality, reliability, and flexibility are all critical for growth. Peter Soelkner, Vetter Managing Director offers his thoughts on these and other issues in a roundtable of industry and academic leaders.
• Dual-chamber systems in parenteral drug delivery
  Author: Thomas Otto
  Medium: Pharmaceutical Technology, May 2011
  Biologics present a challenge to both the manufacturer and end-user. They usually must be formulated as parenterals. In liquid form, however, they often are unstable because of their complex structure and composition. In that case, they must be manufactured using highly specialized processes, such as lyophilization (i.e., freeze-drying), which nearly eliminates stability issues. Reducing a compound's sensitivity to temperature prolongs its shelf-life, but reconstitution can be cumbersome as it involves multiple steps that can increase the potential for error. Dual-chamber technology provides an effective alternative as it combines the lyophilized drug and diluent in a closed system, thereby enabling reconstitution in a few simple steps.
• What does it take for a CMO to Achieve Preferred Provider Status, explained by Vetter Managing Director Peter Soelkner
  Author: Peter Soelkner
  Medium: Pharmaceutical Technology, March 2011
  In an increasingly competitive and changing life sciences market, achieving preferred provider status is a difficult task. Anticipating customer needs, continuous investment in capacity and new technologies, in addition to offering high quality, reliability, and flexibility are all critical to the approach. Peter Soelkner, Vetter Managing Director, offers his thoughts on these and other issues in a roundtable of leading contract service providers.
• Trends in Prefills – Staying Competitive in a Rapidly Changing Market
  Author: Oskar Gold
  Medium: Pharmaceutical Technology Europe, March 2011
  What are the latest trends in prefilled systems and how do they apply to growth and market share? New competition resulting from globalization, cost containment measures designed to reduce overall costs, and an ever-changing regulatory environment create significant competitive pressures for the players in the healthcare market.
  Oskar Gold, Vice President, Key Account Management & Corporate Marketing, at Vetter, shares his thoughts.
• The importance of effective Project Management – why planning ahead will help achieve success
  Author: Peter Soelkner
  Medium: BioPharm International, February 2011
  Achieving success in the early stage product development area is very difficult and includes high hurdles. Small biotech companies, in particular, will have a better chance of reaching their goals when a project management strategy is developed and put in place at the outset in concert with a trusted development and manufacturing partner. In BioPharm International Peter Soelkner, Vetter managing director, offers insight into how companies can develop a well-integrated project management strategy to help achieve drug development success.
• Development Game Plan – Managing Director Peter Soelkner explains in International Clinical Trials
  Author: Peter Soelkner
  Medium: International Clinical Trails, February 2011
  Can your choice of a CMO help you win the drug development game?
  Winning the drug development game takes more than a good compound, hard work and capital. It also requires selecting the right business partners that can help make the difference between not just success or failure of a project, but even the survival of the company itself. Peter Soelkner, Vetter managing director, offers insights on how identifying and hiring the most suitable contract manufacturer for your business can help manage processes and facilitate decision-making during early clinical drug development.
• Managing Customer Relationships? Think Mutual Success
  

  Author: Peter Soelkner
  Medium: Life Science Leader, December 2010
  Managing effective customer relationships requires mutual understanding and effective communication. It begins with a clear understanding of the expectations of your customer and then managing these expectations by adding value to every step of the process. Making every effort to cultivate and grow the relationship as time passes creates a natural desire for mutual success and in a win-win scenario.

• Beyond Syringe Filling
  Author: Thomas Otto
  Medium: Contract Pharma, November/December 2010
  A CMO has to meet the ever- increasing standards of global regulatory bodies, particularly in manufacturing of combination drug-delivery systems like pens and autoinjectors. By using Vetter Secondary Packaging as an example, Thomas Otto illustrates how ventilation, air-conditioning as well as material and personnel flow need to be organized to meet the latest quality and safety standards.
• Product Lifecycle Management - Create Value for your Product and a Future for your Company
  Author: Max Horn
  Medium: International Pharmaceutical Industry, October 2010
  Is product lifecycle management or “PLM,” just another “flavor of the month” or can its incorporation into the manufacturing and marketing efforts of a company actually help improve productivity and profitability? Our rapidly evolving pharmaceutical and biotechnology industry offers insight into how PLM is quickly gaining increasing importance and how it is playing a significant role in the overall success of a product.
• Successfully managing CMO-client relationships
  Author: Peter Soelkner
  Medium: Pharmaceutical Technology Europe, September 2010
  Why is the CMO-client relationship so important to the product development process? And how can contract manufacturer and customer build a solid, productive union? The secret lies in specific processes and approaches that create a truly collaborative environment, which, in turn, yields bottom-line results. Peter Soelkner explains.
• Project Management: The secret to success
  Author: Peter Soelkner
  Medium: Life Science Leader, June 2010
  Discover how project management enhances moving new products through the development process swiftly and efficiently. Peter Soelkner discusses in this article how project management provides the tools and methods to coordinate activities, mitigate issues and keep drug development programs on track.
• Chicago technology park grows despite economy
  Author: Mike Isaacs
  Medium: Skokie Review, June 2010
  The Skokie Review profiles the Illinois Science + Technology Park, where Vetter is building its new Chicago facility. The article discusses the Park’s impressive short-term growth and long-term prospects, and includes Vetter’s role as an important new member of the community.
• Biotechnology in your backyard – Growing businesses continue tradition of Chicagoland being a world-class technology sector
  Medium: Chicago Tribune, May 2010
  Vetter was one of three organizations profiled in a special Chicago Tribune insert on the BIO Convention, which took place in Chicago this May. The piece describes Vetter as an important new contributor to a vibrant and growing biotechnology community in the Midwest. Included are an overview of Vetter’s Chicago facility and the reasons the company chose the Midwest to locate its new site. 
• An ideal location for VDS Chicago
  The Illinois Science + Technology Park in Skokie, Illinois
  Medium: iBIO BioLogical Quarterly, April 2010
  The Illinois Science + Technology Park in Skokie combines the traditional with the modern in a suitable location. More than 70 years ago, life-sciences companies were already established in the location. Today, it is the site of a modern technology park that is very well connected to Chicago, a hub of science and biotechnology and of North America's pharmaceutical and biotechnology industries. An article in the spring edition of iBIO's BioLogical Quarterly provides an overview of the Technology Park's history and current significance.
• A new paradigm for aseptic filling
  Author: Angelo DePalma, Editor
  Medium: GEN, April 2010
  Aseptical filling is one of the most dynamic production steps involving constant technical innovations. The profound changes taking place in the industry are shifting the production paradigm: Nowadays, high-tech processes are being sought to handle complex, biopharmaceutical molecules. The drugs themselves demand special handling since they are quite sensitive to temperature and light. Angelo DePalma from GEN examines the developments in the sector in a report with Vetter's Managing Director Peter Soelkner.
• Vetter’s on-site know-how
  Author: Editor, Gil Roth
  Medium: Contract Pharma, April 2010
  Two-thirds of all the active substances in phases I and II of clinical development originate in the United States. Many pharmaceutical and biotech companies located there face the challenge of having to save time and money before introducing a drug to market. In an interview with Contract Pharma's Gil Roth, Vetter Managing Director Peter Soelkner spoke about the services of the company’s new facility in Skokie. He explains why the company decided to make this move in the US and what strategy the contract manufacturer is pursuing in doing so.
• Solutions for future-oriented filling
  Author: Erik Greb, Editor Equipment and Processing Report
  Medium: Pharmaceutical Technology North America (online)
  Biotechnology holds enormous promise in the worldwide treatment of devastating diseases. Vetter Managing Director Thomas Otto spoke with Erik Greb from Equipment and Processing Report about what the biotech revolution means for drug-delivery systems and manufacturing processes. The discussion includes the potential applications and advantages of pre-filled syringes. 
• Vetter Development Services USA Inc.
  Interviewed: Peter Soelkner, Managing Director of Vetter Pharma International
  Medium: Pharmaceutical Outsourcing
  In late 2009, Vetter unveiled its new Chicago manufacturing facility: Vetter Development Services USA Inc. The facility will fill small batches for early clinical development projects – from preclinical to Phase IIb. In an interview with Pharmaceutical Outsourcing, Peter Soelkner discussed the services of the new Vetter site, along with its advantages for filling trial material. 
• Vetter Launches New US Facility for Clinical Trials Materials
  Author: Laura Bush, Editor in chief BioPharm International
  Medium: BioPharm International, 2nd December 2009
  December 1 marked the launch of the new production site Vetter Development Services USA Inc. In the future, Vetter, one of the leading pharmaceutical service providers, will be in chicago to support its customers with the filling of samples for preclinical as well as phase I and II. Laura Bush, editor in chief of BioPharm International, was present at the opening and reported on the site.

• Change presents an opportunity for new partnerships
  Author: Fedra Pavlou, editor in chief Pharmaceutical Technology Europe
  Medium: pharmtech.com, 1st November 2009
  How can manufacturers and service providers react most effectively to the challenges and developments in the pharmaceutical and biotech industries? That was the topic discussed by experts and industry representatives at the 2nd Vetter Drug Management Leadership Conference. Fedra Pavlou, editor in chief of Pharmaceutical Technology Europe reported on the event and the results.

• Delivering Complex Injectables: Process Challenges and Solutions
  Author: Joerg Zimmermann
  Medium: PMPS, February 2009
  The development of sophisticated medications for previously unmet medical needs has created a whole new breed of challenges for the pharmaceutical industry. The very sophistication of these new drugs has dramatically changed the processes required to produce them. By the same token, the products themselves must be differentiated on the market place in order to achieve commercial success.